BioCentury
ARTICLE | Clinical News

Arverapamil: Completed Phase III enrollment

April 6, 2009 7:00 AM UTC

AGI completed enrollment of 100 patients in the 1-year, open-label, international Phase III ARDIS-3 safety trial evaluating oral Rezular in patients. ...